DarioHealth announces executive changes and new CFO appointment

NEW YORK – DarioHealth Corp. (NASDAQ:DRIO), a Delaware-incorporated company specializing in medical instruments and apparatus trading at $0.73 per share, announced the resignation of its Chief Financial Officer (CFO), Zvi Ben-David, effective May 15, 2025. According to InvestingPro data, the company has shown strong revenue growth of 33% over the last twelve months, despite challenging market conditions. The company stated that Ben-David’s departure is for personal reasons and not related to any disagreements over company operations, policies, or practices.

Simultaneously, the company’s Board of Directors has appointed Chen Franco-Yehuda as the new CFO, Treasurer, and Secretary, also effective May 15, 2025. Franco-Yehuda, 41, brings a wealth of experience to DarioHealth, having previously served as CFO at Pluri Inc. (NASDAQ:TASE:PLUR) and held roles at PricewaterhouseCoopers (PwC) and the Open University of Israel. She is also a board member at Brenmiller Energy Ltd. (NASDAQ:BRNG).

Under the terms of her employment agreement, Franco-Yehuda will receive a monthly salary of approximately $22,245 and is eligible for a bonus of up to six times her base salary based on achieving certain milestones. The agreement includes a severance package, a non-competition clause, and other standard benefits.

Additionally, the company has granted Franco-Yehuda 500,000 restricted shares of common stock, which will vest over three years. This grant is part of the company’s Amended and Restated 2020 Equity Incentive Plan.

In relation to Ben-David’s departure, DarioHealth has entered into a separation agreement with him, retaining his expertise as a member of the advisory board. Ben-David will receive monthly payments starting from July 1, 2025, through October 31, 2027, as compensation for his notice period and accrued vacation.

The changes in DarioHealth’s executive team come as the company continues to navigate the highly competitive medical device industry. With a current ratio of 2.44 and analysts projecting improved earnings for 2025, the company appears positioned for potential growth. These executive moves are based on a press release statement and aim to ensure a smooth transition and continued strategic leadership for the company. For deeper insights into DarioHealth’s valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US stocks.

In other recent news, DarioHealth Corp. reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -$0.08, compared to the forecasted -$0.2267. The company also exceeded revenue projections, reporting $7.6 million against the anticipated $7.51 million, marking a year-over-year revenue growth of 110%. Additionally, DarioHealth has entered a strategic partnership with a national benefit plan administrator to expand its AI-driven digital health solutions to employers, contributing to recurring revenues since January 2025. The collaboration focuses on GLP-1 support for cardiometabolic conditions, aiming to reduce healthcare costs and improve chronic condition management.

DarioHealth has been granted an additional 180 days to meet Nasdaq’s minimum bid price requirement, extending the compliance deadline to September 15, 2025. The company is exploring options like a potential stock split to address the bid price deficiency. Meanwhile, Stifel analysts adjusted their price target for DarioHealth to $2.00 from $3.50 but maintained a Buy rating, noting the company’s modest sequential revenue growth and potential impacts from customer base transitions. DarioHealth is negotiating two substantial contracts expected to contribute to revenue in the second half of 2025 and aims to achieve breakeven free cash flow by the end of the year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.